Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H. El-Serag, A. Mason.
Rising incidence of hepatocellular carcinoma in the United States.
N Engl J Med, 340 (1999), pp. 745-750
[2.]
X. Bosch, J. Ribes, J. Borràs.
Epidemiology of primary liver cancer.
Semi Liver Dis, 19 (1999), pp. 271-285
[3.]
M. Colombo, R. De Franchis, E. Del Ninno, A. Sangiovanni, C. De Fazio, M. Tommasini, et al.
Hepatocellular carcinoma in Italian patients with cirrhosis.
N Engl J Med, 325 (1991), pp. 675-680
[4.]
J.M. Llovet, J. Bruix.
Early diagnosis and treatment of hepatocellular carcinoma.
Baillieres Best Pract Res Clin Gastroenterol, 14 (2000), pp. 991-1008
[5.]
M. Sherman.
Screening for hepatocellular carcinoma.
Bailliere's Clinical Gastroenterology, 13 (1999), pp. 623-635
[6.]
J. Bruix.
Treatment of hepatocellular carcinoma.
Hepatology, 25 (1997), pp. 259-262
[7.]
J.M. Llovet, C. Brú, J. Bruix.
Prognosis of hepatocellular carcinoma: the BCLC staging classification.
Sem Liver Dis, 19 (1999), pp. 329-339
[8.]
P.C. Prorok.
Epidemiologic approach for cancer screening. Problems in design and analysis of trials.
Am J Pedi Hem Onco, 14 (1992), pp. 117-128
[9.]
F.P. Sarasin, E. Giostra, A. Hadengue.
Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh Class A cirrhosis.
Am J Med, 171 (1996), pp. 422-434
[10.]
J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni Burroughs, et al.
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference.
J Hepatol, (2001),
[11.]
P. Johnson, J. Bruix.
Hepatocellular carcinoma and the art of pronostication.
J Hepatol, 31 (2000), pp. 1006-1008
[12.]
International Union Against Cancer (UICC).
TNM classification of malignant tumours. (5.a ed.).
pp. 74-77
[13.]
R.N.H. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, R. Williams.
Transection of the oesophagus for bleeding oesophageal varices.
Br J Surg, 60 (1973), pp. 646-664
[14.]
J.M. Llovet, J. Bruix, J. Fuster, A. Castells, J.C. García-Valdecasas, L. Grande, et al.
Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power.
Hepatology, 27 (1998), pp. 1572-1577
[15.]
K. Okuda, T. Ohtsuki, H. Obata, M. Tomimatsu, N. Okazaki, H. Hasegawa, et al.
Natural history of hepatocellular carcinoma and prognosis in relation to treatment.
Cancer, 56 (1985), pp. 918-928
[16.]
S. Chevret, J.C. Trinchet, D. Mathieu, A. Rached, M. Beaugrand, C. Chastang.
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.
J Hepatol, 31 (1999), pp. 133-141
[17.]
J.M. Llovet, J. Bruix, G.J. Gores.
Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy.
Hepatology, 31 (2000), pp. 1019-1021
[18.]
J.M. Llovet, J. Fuster, J. Bruix.
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.
Hepatology, 30 (1999), pp. 1434-1440
[19.]
J. Bruix, A. Castells, J. Bosch, F. Feu, J. Fuster, J.C. García-Pagán, et al.
Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure.
Gastroenterology, 111 (1996), pp. 1018-1022
[20.]
The Liver Cancer Study Group of Japan.
Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcer in Japan.
Cancer, 74 (1994), pp. 2772-2780
[21.]
Y. Muto, H. Moriwaki, M. Ninomiya, S. Adachi, A. Saito, T.K. Takasaki, et al.
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.
N Engl J Med, 334 (1996), pp. 1561-1567
[22.]
W.Y. Lau, T.W. Leung, S.K. Ho, M. Chan, D. Machin, J. Lau, et al.
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.
Lancet, 353 (1999), pp. 797-801
[23.]
E. Mor, R. Tur Kaspa, P. Sheiner, M.E. Shwartz.
Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.
Ann Intern Med, 129 (1998), pp. 643-653
[24.]
H. Bismuth, P.E. Majno, R. Adam.
Liver transplantation for hepatocellular carcinoma.
Semi Liver Dis, 19 (1999), pp. 311-322
[25.]
V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti.
Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis.
N Engl J Med, 334 (1996), pp. 693-699
[26.]
J.M. Llovet, J. Bustamante, A. Castells, R. Vilana, M. Ayuso, M. Sala, et al.
Prospective follow-up of untreated hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.
Hepatology, 29 (1999), pp. 62-67
[27.]
M. Schwartz, M. Sung, S. Emre.
Liver transplantation for hepatocellular carcinomas > 5 cm diameter: results of a multimodality protocol [resumen].
Abstracts of the 23rd Annual Meeting of the American Society of Transplant Surgeons, Chicago, (mayo 1997),
[28.]
J.M. Llovet, X. Mas, J. Aponte, J. Fuster, M. Navasa, J. Bruix.
Radical treatment of hepatocellular carcinoma during the waiting list for orthotopic liver transplantation: a cost-effectiveness analysis on an intention-to-treat basis.
Hepatology, 30 (1999), pp. 223A
[29.]
F. Sarasin, P. Majno, J.M. Llovet, J. Bruix, J. Mentha, A. Hadengue.
Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness perspective.
Hepatology, 33 (2001), pp. 1073-1079
[30.]
R. Vilana, J. Bruix, C. Brú, C. Ayuso, M. Solé, J. Rodés.
Tumor sizes determines the efficacy of percutaneous ethanol injection for treatment of small hepatocellular carcinoma.
Hepatology, 16 (1992), pp. 353-357
[31.]
J.M. Llovet, J. Bruix, S. Capurro, R. Vilana.
for the Barcelona Clínic Liver Cancer Group. Long-term survival after ethanol injection for small hepatocellular carcinoma in 100 cirrhotic patients. Relevance of maintained success.
J Hepatol, 30 (1999), pp. 100A
[32.]
T. Livraghi, A. Giorgio, G. Marin, A. Salmi, I. de Sio, et al.
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.
Radiology, 197 (1995), pp. 101-108
[33.]
J. Bruix, J.M. Llovet.
Locoregional treatments for hepatocellular carcinoma. Bailliere's Clinical.
Gastroenterology, 13 (1999), pp. 611-622
[34.]
J. Bruix, J.M. Llovet, A. Castells, X. Montañà, C. Brú, M.C. Ayuso, et al.
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma. Results of a randomizated controlled trial in a single institution.
Hepatology, 27 (1998), pp. 1578-1583
[35.]
G. Pelletier, A. Roche, O. Ink, M.L. Anciaux, S. Dehry, P. Rougier, et al.
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
J Hepatology, 11 (1990), pp. 181-184
[36.]
Group d'Etude et de Traitement de Carcinome Hepatocellulaire.
A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.
N Engl J Med, 332 (1995), pp. 1256-1261
[37.]
G. Pelletier, M. Ducreux, F. Gay, M. Luboinsky, H. Hagege, T. Dao, et al.
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial.
J Hepatol, 29 (1998), pp. 129-134
[38.]
M. Madden, J. Kringe, S. Bailey, S.L. Beningfield, C. Geddes, I.D. Werner, et al.
Randomized trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma.
Gut, 34 (1993), pp. 1598-1600
[39.]
D.Y. Lin, Y.F. Liaw, T.Y. Lee, C.M. Lai.
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial.
Gastroenterology, 94 (1988), pp. 453-456
[40.]
F.J. Martínez Cerezo, A. Tomás, L. Donoso, J. Enríquez, C. Guarner, J. Balanzó, et al.
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma.
J Hepatol, 20 (1994), pp. 702-706
[41.]
A. Castells, J. Bruix, C. Brú, C. Ayuso, M. Roca, L. Boix, et al.
Treatment of hepatocellular carcinoma with tamoxifen: a doubleblind placebo-controlled trial in 120 patients.
Gastroenterology, 109 (1995), pp. 917-922
[42.]
CLIP Group.
Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial.
Lancet, 352 (1998), pp. 17-20
[43.]
S. Rossi, F. Fornari, L. Buscarini.
Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma.
J Interv Radiol, 8 (1993), pp. 97-103
[44.]
S. Rossi, M. Di Stasi, E. Buscarini, P. Quaretti, F. Garbagnati, L. Squassante, et al.
Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.
AJR, 167 (1996), pp. 759-768
[45.]
S. Rossi, E. Buscarini, F. Garbagnati, M. Di Stasi, P. Quaretti, M. Rago, et al.
Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode.
AJR, 170 (1998), pp. 1015-1022
[46.]
S. Rossi, F. Garbagnati, R. Lencioni, H.P. Allgaier, A. Marchiano, F. Fornari, et al.
Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply.
Radiology, 217 (2000), pp. 119-126
[47.]
S.A. Curley, F. Izzo, P. Delrio, L.M. Ellis, J. Granchi, P. Vallone, et al.
Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.
Ann Surg, 230 (1999), pp. 1-8
[48.]
A.S. Pearson, F. Izzo, R.Y. Fleming, L.M. Ellis, P. Delrio, M.S. Roh, et al.
Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies.
Am J Surg, 178 (1999), pp. 592-599
[49.]
S.A. Curley, F. Izzo, L.M. Ellis, J. Nicolas Vauthey, P. Vallone.
Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.
Ann Surg, 232 (2000), pp. 381-391
[50.]
T. Livraghi, S.N. Goldberg, S. Lazzaroni, F. Meloni, L. Solbiati.
Gazelle GS small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection.
Radiology, 210 (1999), pp. 655-661
[51.]
T. Livraghi, S.N. Goldberg, S. Lazzaroni, F. Meloni, T. Ierace, L. Solbiati, et al.
Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.
Radiology, 214 (2000), pp. 761-768
[52.]
S.N. Goldberg, G.S. Gazelle, C.C. Compton, P.R. Mueller, K.K. Tanabe.
Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.
Cancer, 88 (2000), pp. 2452-2463
[53.]
A. Grasso, A.F. Watkinson, J.M. Tibballs, A.K. Burroughs.
Radiofrequency ablation in the treatment of hepatocellular carcinoma— a clinical viewpoint.
J Hepatol, 33 (2000), pp. 667-672
[54.]
H. Rhim, G.D. Dodd 3rd.
Radiofrequency thermal ablation of liver tumors.
J Clin Ultrasound, 27 (1999), pp. 221-229
[55.]
J.T. De Sanctis, S.N. Goldberg, P.R. Mueller.
Percutaneous treatment of hepatic neoplasms: a review of current techniques.
Cardiovasc Intervent Radiol, 21 (1998), pp. 273-296
[56.]
G. Dodd III, M. Soulen, R. Kane, T. Livraghi, W. Lees, Y. Yamashita, et al.
Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough.
RadioGraphics, 20 (2000), pp. 9-27
[57.]
N. Honda, Q. Guo, H. Uchida, H. Ohishi, Y. Hiasa.
Percutaneous saline injection therapy for hepatic tumors: an alternative to percutaneous ethanol injection therapy.
Radiology, 190 (1994), pp. 53-57
[58.]
K. Ohnishi, H. Yoshioka, S. Ito, K. Fujiwara.
Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma.
Hepatology, 27 (1998), pp. 67-72
[59.]
D. Hashimoto, M. Takami, Y. Idezuki.
In deph radiation therapy by YAG laser for malignant tumors in the liver under ultrasonic imaging.
Gastroenterology, 88 (1985), pp. 1663A
[60.]
R. Murakami, S. Yoshimatsu, Y. Yamashita, T. Matsukawa, M. Takahashi, K. Sagara.
Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation.
Am J Roentgenol, 164 (1995), pp. 1159-1164
[61.]
J.K. Steifert, T. Junginger, D.L. Morris.
A collective review of the world literature on hepatic cryotherapy.
JR Coll Surg Edinb, 43 (1998), pp. 141-154
[62.]
G. Dionne, M. Dufour, J. Morin, C. Moisan.
MR guided cryosurgery of liver tumors with MnDPDP: AS pilote study.
Galil Medical-IRAD Abstracts-June, (2000), pp. 5-7
[63.]
B. Sangro, J. Ruiz, C. Qian, J. Prieto.
Terapia génica en las enfermedades hepáticas.
Gastroenterol Hepatol, 23 (2000), pp. 394-402
[64.]
J.M. Llovet, R. Vilana, C. Brú, L.l. Bianchi, J.M. Salmerón, M. Sala, et al.
Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma.
Hepatology, 33 (2001), pp. 1124-1129
[65.]
W. Lees, A. Gillams.
Complications of radiofrequency and laser ablation in liver metastases: incidence and management.
Eur J Radiol, 1 (2000), pp. 260
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
